| | | 委托理财金额：人民币2,000万元。 股票代码：600272 股票简称：开开实业 编号：2025-075 900943 开开 B 股 上海开开实业股份有限公司 关于使用闲置自有资金购买银行理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 委托理财受托方：宁波银行股份有限公司上海静安支行（以下简称： "宁波银行"）； 委托理财产品类型：结构性存款； 委托理财期限：180天； 履行的审议程序：2025年4月28日上海开开实业股份有限公司（以下 简称： "公司"）召开第十届董事会第二十五次会议，以9票同意、0票反 对、0票弃权的表决结果，审议通过了《关于董事会授权购买低风险理财产 品的议案》，授权公司总经理室在2025年4月至2026年4月期间，阶段性的 继续利用短期闲置资金总金额不超过人民币1.8亿元，购买低风险理财产品。 在上述额度内资金可以滚动使用。在资金额度的使用期限内任一时点的交 易金额（含前述投资的收益进行再投资的相关金额）不超过该投资额度。 本议案无需提交股东大会审议。 特 ...

关于公司董事会完成换届选举及 聘任高级管理人员、证券事务代表的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 上海开开实业股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日召开公司 2025 年第一次临时股东大会，选举产生了公司第十 一届董事会成员。同日，公司召开第十一届董事会第一次会议，审议 通过了选举公司董事长、董事会专门委员会委员、聘任公司高级管理 人员及证券事务代表的相关议案。现将具体情况公告如下： 一、公司第十一届董事会组成情况 公司第十一届董事会由 9 名董事组成（简历见附件）。其中，非 独立董事 6 名，独立董事 3 名。公司董事会下设战略与 ESG 委员会、 薪酬与考核委员会、审计委员会、提名委员会四个专门委员会。 （一）董事会成员 董事长：庄虔贇 | 证券代码：600272 | 证券简称：开开实业 | | | | 编号：2025-074 | | --- | --- | --- | --- | --- | --- | | 900943 | | 开开 | B | 股 | | 上海开开实业股 ...

证券代码：600272 900943 证券简称：开开实业 开开 B 股 公告编号：2025-072 上海开开实业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 (一) 股东大会召开的时间：2025 年 11 月 21 日 (二) 股东大会召开的地点：上海市静安区昌平路 710 号 7 楼会议室 (三) 出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 121 | | --- | --- | | 其中：A 股股东人数 | 118 | | 境内上市外资股股东人数（B 股） | 3 | | 2、出席会议的股东所持有表决权的股份总数（股） | 94,419,871 | | 其中：A 股股东持有股份总数 | 94,415,071 | | 境内上市外资股股东持有股份总数(B 股) | 4,800 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份总数的 比 ...

股票代码：600272 股票简称：开开实业 编号：2025-073 900943 开开 B 股 上海开开实业股份有限公司 第十一届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海开开实业股份有限公司（以下简称"公司"）于 2025 年 11 月 21 日召开 2025 年第一次临时股东大会，选举产生了公司第十一届 董事会成员。（具体详见 2025 年 11 月 22 日《上海证券报》《香港商 报》和上海证券交易所网站 www.sse.com.cn 相关公告） 为保证董事会工作的连续性，董事庄虔贇女士在会议上对本次会 议的通知时间等事项向与会董事作出了说明，经全体董事一致同意， 豁免本次会议的通知时限要求。公司第十一届董事会第一次会议于 2025 年 11 月 21 日在公司会议室以现场表决方式召开，本次会议应 到董事 9 名，实到董事 9 名，公司高级管理人员列席了会议。全体与 会董事一致推举董事庄虔贇女士主持本次会议，会议的召开和程序符 合有关法律、行政法规、部门规章、规范性文件和公司章程的 ...

南财智讯11月21日电，开开实业公告，开开实业本次委托理财投资金额为人民币2000万元，投资品种为 结构性存款，资金来源为公司短期闲置的自有资金，投资期限为180天。该事项已经公司第十届董事会 第二十五次会议审议通过，授权公司总经理室在2025年4月至2026年4月期间，阶段性使用短期闲置资金 总金额不超过1.8亿元购买低风险理财产品，上述额度内资金可滚动使用，无需提交股东大会审议。 ...

Core Viewpoint - The stock of Kaikai Industrial has experienced a decline of 5.90% year-to-date, with a recent drop of 2.06% on November 21, 2023, indicating potential concerns among investors regarding its performance in the market [1]. Financial Performance - For the period from January to September 2025, Kaikai Industrial reported a revenue of 825 million yuan, reflecting a year-on-year growth of 10.76%. However, the net profit attributable to shareholders decreased by 62.81% to 12.87 million yuan [2]. - The company has cumulatively distributed 191 million yuan in dividends since its A-share listing, with 34.75 million yuan distributed over the past three years [3]. Stock Market Activity - As of November 21, 2023, Kaikai Industrial's stock price was 14.28 yuan per share, with a trading volume of 153 million yuan and a turnover rate of 6.56%, resulting in a total market capitalization of 3.751 billion yuan [1]. - The stock has seen a net outflow of 10.55 million yuan from major funds, with significant selling pressure observed [1]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Kaikai Industrial was 33,700, a decrease of 7.03% from the previous period. The top ten circulating shareholders include notable entities such as China Merchants Securities (Hong Kong) Co., Ltd. and BOCI Securities Limited, with stable holdings [2][3].

截至9月30日，开开实业股东户数3.37万，较上期减少7.03%；人均流通股0股，较上期增加0.00%。2025 年1月-9月，开开实业实现营业收入8.25亿元，同比增长10.76%；归母净利润1286.78万元，同比减少 62.81%。 责任编辑：小浪快报 分红方面，开开实业A股上市后累计派现1.91亿元。近三年，累计派现3474.90万元。 开开实业今年以来股价跌9.66%，近5个交易日跌2.49%，近20日涨1.63%，近60日跌1.22%。 今年以来开开实业已经1次登上龙虎榜，最近一次登上龙虎榜为1月2日，当日龙虎榜净买入-1120.05万 元；买入总计5518.17万元 ，占总成交额比8.51%；卖出总计6638.22万元 ，占总成交额比10.24%。 资料显示，上海开开实业股份有限公司位于上海市静安区昌平路678号一楼，成立日期1997年8月4日， 上市日期2001年2月28日，公司主营业务涉及以中医药流通、中医药学服务(中医问诊服务)和服装批 发、零售为主营业务。主营业务收入构成为：批发类74.48%，零售类18.18%，卫生服务类4.42%，租赁 类1.77%，其他1.14%。 机构持仓方面， ...

Market Overview - The medical consumables supply chain SPD sector experienced a decline of 1.42% on November 19, with Ailong Technology leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Key stocks in the medical consumables supply chain SPD sector showed mixed performance, with Jianfa Zhixin rising by 3.19% to a closing price of 34.00, while several others, including Guoyao Yici and Jiuzhoutong, saw declines of 0.55% and 0.59% respectively [1] - The trading volume and turnover for Jianfa Zhixin were 180,800 hands and 620 million yuan, respectively [1] Capital Flow - The medical consumables supply chain SPD sector saw a net outflow of 99.05 million yuan from main funds, while retail investors contributed a net inflow of 74.72 million yuan [2] - Notable individual stock capital flows included Jianfa Zhixin with a net inflow of 70.39 million yuan from main funds, while Ailong Technology experienced a net outflow of 2.99 million yuan [3]

Group 1 - The core viewpoint of the news is that Kaikai Industrial's stock has experienced fluctuations, with a recent decline of 2.01% and a year-to-date drop of 7.02% [1] - As of November 19, the stock price is reported at 14.11 yuan per share, with a total market capitalization of 3.706 billion yuan [1] - The company has seen a net outflow of main funds amounting to 4.33 million yuan, with significant buying and selling activities recorded [1] Group 2 - Kaikai Industrial operates primarily in the pharmaceutical distribution sector, with its main business revenue composition being 74.48% from wholesale, 18.18% from retail, 4.42% from health services, and 1.77% from leasing [1] - For the period from January to September 2025, the company achieved a revenue of 825 million yuan, reflecting a year-on-year growth of 10.76%, while the net profit attributable to shareholders decreased by 62.81% to 12.87 million yuan [2] - The company has distributed a total of 191 million yuan in dividends since its A-share listing, with 34.75 million yuan distributed over the past three years [3]

Market Overview - The pharmaceutical commercial sector experienced a decline of 0.92% on November 18, with Yao Yigou leading the drop [1] - The Shanghai Composite Index closed at 3939.81, down 0.81%, while the Shenzhen Component Index closed at 13080.49, down 0.92% [1] Stock Performance - Notable gainers included: - Ren Da Medical (603108) with a closing price of 15.97, up 2.90% and a trading volume of 278,200 shares, totaling 442 million yuan [1] - People's Tongtai (600829) with a closing price of 17.72, up 6.49% and a trading volume of 1,148,700 shares, totaling 1.902 billion yuan [1] - Major decliners included: - Yao Yigou (300937) with a closing price of 33.95, down 6.37% and a trading volume of 115,000 shares, totaling 396 million yuan [2] - Luhua Pharmaceutical (002788) with a closing price of 10.29, down 5.86% and a trading volume of 467,300 shares, totaling 489 million yuan [2] Capital Flow - The pharmaceutical commercial sector saw a net outflow of 706 million yuan from institutional investors, while retail investors contributed a net inflow of 705 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing while retail investors remained active [2] Individual Stock Capital Flow - Ren Da Medical (603108) had a net inflow of 49.2 million yuan from institutional investors, while retail investors saw a net outflow of 65.5 million yuan [3] - Yao Yigou (300937) experienced a significant net outflow of 560.4 million yuan from institutional investors [3] - The data reflects varying levels of investor confidence across different stocks within the sector [3]